2
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
Conditions
Carcinoma, Non-Small-Cell Lung
24
Lung Neoplasms
14
Carcinoma, Medullary
14
Neoplasm Metastasis
12
Neoplasms
10
Thyroid Neoplasms
8
Breast Neoplasms
8
Glioma
6
Prostatic Neoplasms
5
Glioblastoma
5
Squamous Cell Carcinoma of Head and Neck
4
Gliosarcoma
4
Colorectal Neoplasms
4
Brain Neoplasms
4
Pancreatic Neoplasms
3
Ovarian Neoplasms
3
Head and Neck Neoplasms
3
Carcinoma, Renal Cell
3
Adenocarcinoma
3
Urinary Bladder Neoplasms
2
Thyroid Cancer, Papillary
2
Stomach Neoplasms
2
Recurrence
2
Rectal Neoplasms
2
Pleural Effusion
2
Kidney Neoplasms
2
Familial medullary thyroid carcinoma
2
Fallopian Tube Neoplasms
2
Esophageal Neoplasms
2
Disease Progression
2
Interventions
Cisplatin
56
Carboplatin
51
pembrolizumab
43
Paclitaxel
42
Gemcitabine
28
Pemetrexed
24
Radiotherapy
21
Magnetic Resonance Spectroscopy
20
Radiotherapy, Intensity-Modulated
18
Cetuximab
18
Docetaxel
17
Specimen Handling
16
Nivolumab
16
Fluorouracil
16
Cyclophosphamide
14
durvalumab
13
Bevacizumab
13
Sorafenib
12
Radiation
11
130-nm albumin-bound paclitaxel
11
Sunitinib
10
Platinum
10
1,2-diaminocyclohexaneplatinum II citrate
10
osimertinib
9
Oxaliplatin
8
Irinotecan
8
Ipilimumab
8
Everolimus
8
Drug Therapy
8
Capecitabine
8
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma
×
vandetanib
×
Clear all
NCT00506051
2016-08-25
ZD6474(Vandetanib) + Alimta Combo Study
Sanofi
Phase 1
Completed
21 enrolled